[Home ] [Archive]   [ فارسی ]  
:: Main :: About us :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 17, Issue 2 (Summer 2020) ::
Sci J Iran Blood Transfus Organ 2020, 17(2): 113-125 Back to browse issues page
Effect of curcumin and sorafenib on AKT gene expression in KG1 and U937 cell lines
R. Pazahr , M. Mohammadikian, E. Ali Asgari Dr., S. Mohammadi Dr., Sh. Rostami Dr., B. Chahardolii Dr., D. Babakhani Dr., M. Nikbakht Dr.
Keywords: Key words: Acute Myeloid Leukemia, Curcumin, Sorafenib
Full-Text [PDF 843 kb]   (379 Downloads)     |   Abstract (HTML)  (1011 Views)
Type of Study: Research | Subject: Hematology and Oncology
Published: 2020/06/30
Full-Text:   (461 Views)
    :References
  1. Hoffbrand AV, Higgs DR, Keeling DM, Mehta AB. Postgraduate Haematology. USA: John Wiley & Sons; 2016. p. 152.
  2. Zand AM, Imani S, Saadati M, Borna H, Ziaei R, Honari H. Effect of age, gender and blood group on blood cancer types. Kowsar Medical J 2010; 15(2): 111-4. [Article in Farsi]
  3. Salemi M, Mohammadi S, Ghavamzadeh A, Nikbakht M. Anti-vascular endothelial growth factor targeting by curcumin and thalidomide in acute myeloid leukemia cells. Asian Pac J Cancer Prev 2017; 18(11): 3055-61.
  4. Chomel JC, Turhan AG. Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget 2011; 2(9): 713-27.
  5. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004; 5(7): 738-43.
 
  1. Gilliland DG,  Jordan  CT,  Felix  CA.  The molecular
basis of leukemia. Hematology Am Soc Hematol Educ Program 2004; 80-97.
  1. Martelli AM, Evangelisti C, Follo MY, Ramazzotti G, Fini M, Giardino R, et al. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells. Curr Med Chem 2011; 18(18): 2715-26.
  2. Osaki M, Oshimura Ma, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004; 9(6): 667-76.
  3. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4(12): 988-1004.
  4. Chen YL, Law PY, Loh HH. Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy. Curr Med Chem Anticancer Agents 2005; 5(6): 575-89.
  5. Zhang  W,   Konopleva   M,   Ruvolo  V, McQueen T,
Evans R, Bornmann W, et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 2008; 22(4): 808-18.
  1. Sacco R, Bargellini I, Gianluigi G, Bertini M, Bozzi E, Altomare E, et al. Complete response for advanced liver cancer during sorafenib therapy: case report. BMC Gastroenterol 2011; 11(1): 4.
  2. Kian MM, Mohammadi S, Tavallaei M, Chahardouli B, Rostami S, Zahedpanah M, et al. Inhibitory effects of arsenic trioxide and thalidomide on angiogenesis and vascular endothelial growth factor expression in leukemia cells. Asian Pac J Cancer Prev 2018; 19(4): 1127-34.
  3. Haghi A, Mohammadi S, Heshmati M, Ghavamzadeh A, Nikbakht M. Anti-vascular endothelial growth factor effects of sorafenib and arsenic trioxide in acute myeloid leukemia cell lines. Asian Pac J Cancer Prev 2017; 18(6): 1655-61.
  4. Aggarwal BB, Banerjee S, Bharadwaj U, Sung B, Shishodia S, Sethi G. Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharmacol 2007; 73(7): 1024-32.
  5. Rao J, Xu DR, Zheng FM, Long ZJ, Huang SS, Wu X, et al. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells. J Transl Med 2011; 9(1): 71.
  6. Johnson CM, Yang S, Sellins KS, Frank GR. Selection of HPRT primers as controls for determination of mRNA expression in dogs by RT-PCR. Vet Immunol Immunopathol 2004; 99(1-2): 47-51.
  7. Fabi F, Grenier K, Parent S, Adam P, Tardif L, Leblanc V, et al. Regulation of the PI3K/Akt pathway during decidualization of endometrial stromal cells. PLoS One 2017; 12(5): e0177387.
  8. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011; 2(3): 135-64.
  9. Scartozzi M, Faloppi L, Svegliati Baroni G, Loretelli C, Piscaglia F, Iavarone M, et al. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study. Int J Cancer 2014; 135(5): 1247-56.
  10. Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 2008; 100(4): 282-4.
  11. Zhang J, Yu J, Xie R, Chen W, Lv Y. Combinatorial anticancer effects of curcumin and sorafenib towards thyroid cancer cells via PI3K/Akt and ERK pathways. Nat Prod Res 2016; 30(16): 1858-61.
  12. Cao H, Wang Y, He X, Zhang Z, Yin Q, Chen Y, et al. Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma. Mol Pharm 2015; 12(3): 922-31.
  13. Rao J, Xu DR, Zheng FM, Long ZJ, Huang SS, Wu X, et al. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells. J Transl Med 2011; 9(1): 71.
  14. Huber S, Oelsner M, Decker T, zum Büschenfelde CM, Wagner M, Lutzny G, et al. Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia 2011; 25(5): 838-47. 
  15. Chen KF, Chen HL, Tai WT, Feng WC, Hsu CH, Chen PJ, et al. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther 2011; 337(1): 155-61.
  16. Safaian N, Czibere A, Bruns I, Fenk R, Reinecke P, Dienst A, et al. Sorafenib (Nexavar®) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. Leuk Res 2009; 33(2): 348-50.
 


 
 
 
 
Sci J Iran Blood Transfus Organ 2020; 17(2): 113-125
Original Article
 
Effect of curcumin and sorafenib on AKT gene
expression in KG1 and U937 cell lines
 
Pazahr R.1, Mohammadikian M.1, Ali Asgari E.2, Mohammadi S.1, Rostami Sh.1,
Chahardolii B.1, Babakhani D.1, Nikbakht M.1
 
 
1Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
2Islamic Azad University South Tehran Branch, Tehran, Iran
 
 
 
Abstract
Background and Objectives
Acute myeloid leukemia is a heterozygous hematologic malignancy that is manifested by the     accumulation of hematopoietics stem cells in peripheral blood and bone marrow. Anticancer effects and  cryotoxic activity of curcumin have been proven frequently in many cancers. Sorafenib is known as an inhibitor of angiogenesis which prevent cells’ survival. In the present study, the effects of curcumin and sorafenib and their combination were evaluated on AML cells.
 
Materials and Methods
In this experimental study, U937 and KG-1 cells were treated with different concentration of curcumin and sorafenib and their combination.  MTT assay was applied to assess the viability of cells.  Percentage of apoptotic cells was evaluated by annexin PI staining. Also Real Time PCR was performed to investigte the level of  AKT mRNA expression.
 
Results
Our data showed that the percentage of apoptotic cells significantly increased in response to treatment with  curcumin (40µM in KG-1 and U937 cell lines), sorafenib (5 µM and 7 µM in U937 and KG-1, respectively) and their combination. Moreover, the mRNA level of AKT gene was downregulated in KG-1 and U937 cells.
 
Conclusions 
Our results suggest that combination of curcumin and sorafenib could lead to promote apoptosis. Furthurermore, downregulation of AKT gene shows that these agents can be considered as effective agents on AML cells. 
 
Key words: Acute Myeloid Leukemia, Curcumin, Sorafenib
 
 
 
 
 
 
Received: 13 Aug 2019
Accepted:  1 Jan  2020
 
 
Correspondence: Nikbakht  M., PhD in Medical Biotechnology. Associated Professor of Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Shariati Hospital.
Postal Code: 1411713131, Tehran, Iran. Tel: (+9821) 84902635; Fax: (+9821) 84902635
:E-mail
m-nikbakht@sina.tums.ac.ir
Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Pazahr R, Mohammadikian M, Ali Asgari E, Mohammadi S, Rostami S, Chahardolii B, et al . Effect of curcumin and sorafenib on AKT gene expression in KG1 and U937 cell lines. Sci J Iran Blood Transfus Organ. 2020; 17 (2) :113-125
URL: http://bloodjournal.ir/article-1-1297-en.html


Volume 17, Issue 2 (Summer 2020) Back to browse issues page
فصلنامه پژوهشی خون Scientific Journal of Iran Blood Transfus Organ
The Scientific Journal of Iranian Blood Transfusion Organization - Copyright 2006 by IBTO
Persian site map - English site map - Created in 0.04 seconds with 31 queries by YEKTAWEB 4319